Medicare will let eligible Part D beneficiaries fill select obesity GLP-1s for $50 a month starting July 1, 2026. That window closes December 31, 2027. It is a temporary CMS demonstration, not a permanent Part D obesity benefit, and the longer BALANCE Part D model that was supposed to follow has been indefinitely delayed.
That combination matters for investors watching Novo Nordisk, Eli Lilly, and the Medicare pharmacy channel. Volume can ramp under a known copay. The coverage path after 2027 is still unsettled.
- CMS set the Medicare GLP-1 Bridge at $50 per month from July 1, 2026 through December 31, 2027 for eligible Part D enrollees.
- KFF reports manufacturers agreed to a $245 net monthly price under the Bridge, while BALANCE for Part D did not clear the roughly 80% plan-enrollment threshold for 2027.
- Medicare.gov lists covered products as Foundayo (tablet), Wegovy (injection or tablet), and Zepbound (KwikPen only). The $50 sits outside Part D, so it does not count toward the deductible or out-of-pocket limit, and Extra Help does not lower it.
A bridge, not a permanent Part D benefit
CMS describes the Bridge as a short-term demonstration under Section 402 authority. It runs outside the normal Part D coverage and payment flow. Plan sponsors do not have to opt in, and they do not carry risk for Bridge claims. Pharmacies collect the $50 and bill a central CMS processor.
That design expands access on a clock. Prior authorizations under the Bridge stay valid through December 31, 2027 unless the patient switches GLP-1s. After that date, KFF notes there is no clear Medicare obesity coverage path unless BALANCE is restarted or Congress changes the statute that still bars Part D from covering weight-loss drugs outside demos.
Covered drugs are narrow. Medicare.gov names Foundayo tablet, Wegovy injection or tablet, and Zepbound KwikPen only. Single-dose Zepbound vials and pens are out. Eligibility hinges on BMI tiers plus listed conditions, with type 2 diabetes, moderate-to-severe sleep apnea, and fatty liver disease steered back to ordinary Part D when those are the covered uses.
Why BALANCE Part D stalled
CMS had pitched a two-step path: Bridge in 2026, then BALANCE in Part D from 2027 into 2031. After the April 20, 2026 plan-sponsor application deadline, CMS said it would not move BALANCE in Medicare for 2027 and would extend the Bridge through year-end 2027 instead.
KFF ties that pause to thin plan interest. CMS had wanted roughly 80% of relevant Part D enrollment in participating sponsors before launching. Major sponsors were reluctant under the original design, and the threshold was not met. Medicaid BALANCE is a separate track: state participation can roll from May 2026, with a July 31, 2026 state application deadline, and is not blocked by the Part D delay.
Gross Medicare GLP-1 spending was already large before obesity demos. KFF cites 21.8 million Medicare claims and $27.5 billion in gross spending in 2024, before rebates. That is the baseline for diabetes and other covered uses. Obesity volume under the Bridge adds a new, time-boxed layer on top.
What investors should watch
This is not a cue to treat every GLP-1 name as a permanent Medicare obesity franchise. The Bridge can support script volume and pharmacy throughput through late 2027 at a fixed $50 beneficiary cost and a $245 manufacturer net. It does not rewrite the statutory exclusion, and it does not lock in BALANCE economics for Part D plans.
Watch three multi-quarter markers. First, whether Bridge utilization and PA volumes ramp after July 2026 the way CMS and manufacturers expect. Second, whether CMS redesigns BALANCE or extends the Bridge again before the 2027 cliff. Third, how Novo Nordisk and Eli Lilly guide Medicare obesity mix versus cash and commercial channels as the demo ages.
For a 50-plus investor, the portfolio question is simple. Who captures durable volume if Medicare obesity coverage becomes structural, and who is exposed if the demo ends without a Part D replacement? The $50 Bridge buys time. It does not buy permanence.
